| 生物活性 | |||
|---|---|---|---|
| 描述 | M2698, an oral, ATP-competitive inhibitor, selectively targets p70S6K and Akt with IC50s of 1 nM for both p70S6K and Akt1/3. It is capable of crossing the blood-brain barrier and exhibits anti-cancer properties. At concentrations ranging from 0.3 nM to 50 M over 72 hours, M2698 dose-dependently curbs the proliferation of breast tumor cell lines, with IC50s between 0.02-8.5 µM. Additionally, at 0.3 and 1 µM for 24 hours, it inhibits p70S6K activity, triggers feedback phosphorylation on Akt, and reduces Akt activity in these cell lines. M2698 indirectly inhibits pGSK3β (IC50=17 nM) and pS6 (IC50=15 nM)[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.22mL 0.44mL 0.22mL |
11.11mL 2.22mL 1.11mL |
22.23mL 4.45mL 2.22mL |
| 参考文献 |
|---|